Issue Date: June 5, 2017
Array licenses cancer compounds to Ono
Array BioPharma has licensed Japan’s Ono Pharmaceutical the right to develop two late-stage oncology compounds, binimetinib and encorafenib, in Japan and South Korea. Array will get $32 million up front and up to $156 million in milestone payments. The compounds are in Phase III studies of patients with BRAF-mutant cancers. Array recently struck a deal to assess binimetinib with two Bristol-Myers Squibb immuno-oncology agents.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society